150 reports of this reaction
2.4% of all CEFADROXIL reports
#11 most reported adverse reaction
NASAL OEDEMA is the #11 most commonly reported adverse reaction for CEFADROXIL, manufactured by Aurobindo Pharma Limited. There are 150 FDA adverse event reports linking CEFADROXIL to NASAL OEDEMA. This represents approximately 2.4% of all 6,348 adverse event reports for this drug.
Patients taking CEFADROXIL who experience nasal oedema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASAL OEDEMA is a less commonly reported adverse event for CEFADROXIL, but still significant enough to appear in the safety profile.
In addition to nasal oedema, the following adverse reactions have been reported for CEFADROXIL:
The following drugs have also been linked to nasal oedema in FDA adverse event reports:
NASAL OEDEMA has been reported as an adverse event in 150 FDA reports for CEFADROXIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASAL OEDEMA accounts for approximately 2.4% of all adverse event reports for CEFADROXIL, making it a notable side effect.
If you experience nasal oedema while taking CEFADROXIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.